This study aims to test a new drug, **AZD2373**, for people with a specific kind of kidney disease called **APOL1-Mediated Kidney Disease (AMKD)**. This condition is linked to specific genes called **G1 and G2**. **UACR** (Urine Albumin to Creatinine Ratio) is a measure used to check kidney health. **Key Points:** - The study will last for **30 weeks**, with participants taking medicine throughout. - Participants must be between **18 and 65 years old** and have the high-risk genes. - The study does not include anyone on kidney replacement therapy or with certain other health conditions. You will be placed in one of the three groups, but neither you nor the researchers will know your group. Around **96 people** will join, with about **32 people in each group**. You won't be eligible if you have **Type 1 Diabetes** or are on certain medications for **Type 2 Diabetes**. If interested, you must be ready to follow study rules and give your consent.